Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

• Sponsor: Peking University People's Hospital (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05302024
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 20.7
• Patients Per Site Per Month: 4.8

Study Details

Study Description

Brief Summary

A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)

Condition or Disease	Intervention/Treatment	Phase
Immune Thrombocytopenia	Drug: Iguratimod	Phase 2

Detailed Description

The investigators are undertaking an open-label, single-arm study of 100 adults with steroid-resistant/ relapse ITP in China. Patients were received Iguratimod treatment. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 100 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Phase 2, Open-label, Single-arm Trial
• Anticipated Study Start Date: Mar 22, 2022
• Anticipated Primary Completion Date: Dec 12, 2023
• Anticipated Study Completion Date: Dec 12, 2023

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Iguratimod treatment Iguratimod is given at a dose of 25 mg bid for 12 weeks.

Drug: Iguratimod; Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.

Outcome Measures

Primary Outcome Measures

1. Durable response [6 months]

   The maintenance of platelet count ≥ 30 x 10^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up.

Secondary Outcome Measures

1. Initial response [1 month]

   Platelet count ≥ 30 x 10^9/L and at least doubling baseline at 1 month

2. Remission [12 months]

   109/ Platelet count >100x 10^9/L at 12 mon

3. Time to response [12 months]

   Time to response was defined as the time from starting treatment to the time to achieve the response

4. Bleeding [12 months]

   Major bleeding: (1) WHO grade 3 or 4 bleeding, (2) Buchanan severe grade, (3) Bolton-Maggs and Moon "major bleeding," (4) IBLS grade 2 or higher, or (5) life-threatening or intracerebral hemorrhage bleeding

5. Adverse events [12 months]

   Adverse events

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia;

• Platelet count of less than 30×10^9/L at enrollment;

• Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation;

• 18 years older;

Exclusion Criteria:

• Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus)

• Congestive heart failure

• Severe arrhythmia

• Nursing or pregnant women

• Aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria

• Creatinine or serum bilirubin levels each 1•5 times or more than the normal range

• Active or previous malignancy

• Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Peking University Insititute of Hematology, Peking University People's Hospital	Beijing	Beijing	China	100010

Sponsors and Collaborators

• Peking University People's Hospital

Investigators

• Principal Investigator: Xiao-Hui Zhang, MD, Peking University People's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Xiao Hui Zhang, Vice president of Peking University Institute of Hematology, Peking University People's Hospital
• ClinicalTrials.gov Identifier: NCT05302024
• Other Study ID Numbers: I-ITP 001
• First Posted: Mar 31, 2022
• Last Update Posted: Mar 31, 2022
• Last Verified: Mar 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Thrombocytopenia; Purpura, Thrombocytopenic, Idiopathic

Study Results

No Results Posted as of Mar 31, 2022